Ethical Dilemma with Stakeholders
You're the CEO of a pharmaceutical company. Your best-selling drug ($2B annual revenue, used by 4 million patients for chronic pain) has…
48-Hour Action Plan: Patient Safety First, Managed Transparency Second Core Decision (Stated Up Front) We report to regulators immediately—voluntarily—and we disclose on the earnings call. The math is brutal and clear: ~500 patients could develop liver failure over 5 years at current prescribing rates (4M ÷ 8,000).Read the full answer
As CEO, my primary fiduciary and ethical duty is to patients, regulators, and long-term shareholder value. The "6-month reporting timeline" cited by legal is almost certainly a misunderstanding of regulatory processes (likely conflating initial adverse event reporting with full label amendment review).Read the full answer